PropertyValue
?:definition
  • A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to as of yet not fully elucidated co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous CD19-targeted CAR-T cells GC007F target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasT (F) CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5417841_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5417841_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all